Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol-Myers Squibb Co.

www.bms.com

Latest From Bristol-Myers Squibb Co.

HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End

Gilead's Biktarvy (B/F/TAF) single tablet is poised to become a huge success, surpassing competitors in the HIV market by far, but the GlaxoSmithKline-backed ViiV Healthcare looks better positioned in the long run.

Market Intelligence Infectious Diseases

In The Hot Seat: Bristol Defends IO Position Amid Sliding Stock And Forecasts

Bristol's stock price dipped after the AACR meeting, where pivotal lung cancer data for Opdivo/Yervoy disappointed relative to Merck's Keytruda/chemo combo, but Bristol still has many immuno-oncology irons in the fire in other indications and expressed confidence in its strategy.

Clinical Trials ImmunoOncology

How Will Novel Agents Impact The HIV Market?

ViiV and Merck are looking to novel mechanisms of action as an opportunity to make up ground on HIV leader Gilead, which has de-emphasized early virology research. 

Research & Development Business Strategies

Roche's IMpower150 Gets AACR Applause But Merck's KEYNOTE-189 Big Winner

Roche’s Tecentriq IMpower150 trial showed Tecentriq plus Avastin plus paclitaxel and carboplatin significantly improved progression free survival compared to Avastin and chemo alone; overall survival data will be coming later this year.

Clinical Trials Cancer
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register